

**March 04, 2025**

**To**

The Chief General Manager  
Listing Operation,  
BSE Limited,  
20th Floor, P. J. Towers,  
Dalal Street, Mumbai – 400 001.

**Scrip Code: 524743**

Dear Sir / Madam,

**Sub:** Intimation under Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")- Intimation of Investment through Rights Issue in FlynnCare Health Innovations Private Limited., Wholly Owned Subsidiary of the Company.

In furtherance to the Objects stated in the offer letter of the Company dated February 04, 2025 and pursuant to Regulation 30(6) read with Schedule III Part A Para A (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Company has made a further investment in the wholly-owned subsidiary of the Company, through rights issue.

We have enclosed herewith the details required under Regulation 30 read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1.**

Kindly take the above information on your record and acknowledge.

Thanking You

Yours Faithfully

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)

**VENKATASUBRAMANIAN**  
Digitally signed by  
VENKATASUBRAMANIAN  
ARAVINDKUMAR  
Date: 2025.03.04 17:21:28 +05'30'

**ARAVINDKUMAR V**  
**COMPANY SECRETARY & COMPLIANCE OFFICER**



**Annexure -1**

**Disclosure under Regulation 30(6) read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	FlynnCare Health Innovations Pvt Ltd ("FCHI") is currently engaged in the business of developing, designing, and providing health technology solutions.  FCHI was incorporated on 29-07-2024.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arm's length"	FCHI, being a wholly owned subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms' length.  Except to the extent of shares held by the Company in FCHI, the Company has no interest in FCHI.
3.	Industry to which the entity being acquired belongs	IT services in HealthCare
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment is a part of utilization of the proceeds as specified in Offer letter dated February 04, 2025 for working capital requirements of FCHI.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Investment of INR 29,50,76,808 (2,202 equity shares on rights basis).
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	There will be no change in the percentage of shareholding of the Company in FCHI. It will continue to remain a wholly owned subsidiary of the Company.

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>FCHI was incorporated on July, 29, 2024 as the wholly owned subsidiary of the Company. FCHI is currently engaged in the business of developing, designing, and providing health technology solutions.</p> <p>FCHI was incorporated on 29-07-2024. Hence, turnover for past 3 years is NA</p>
-----	--	---

\*\*\*



**March 03, 2025**

**To**

The Chief General Manager  
Listing Operation,  
BSE Limited,  
20th Floor, P. J. Towers,  
Dalal Street, Mumbai – 400 001.

**Scrip Code: 524743**

Dear Sir / Madam,

**Sub:** Intimation under Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")- Intimation of Investment through Rights Issue in Time Medical International Ventures (India) Private Limited, Wholly Owned Subsidiary of the Company.

In furtherance to the Objects stated in the offer letter of the Company dated February 04, 2025 and pursuant to Regulation 30(6) read with Schedule III Part A Para A (1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we would like to inform you that the Company has made a further investment in the wholly-owned subsidiary of the Company, through rights issue.

We have enclosed herewith the details required under Regulation 30 read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as **Annexure -1.**

Kindly take the above information on your record and acknowledge.

Thanking You

Yours Faithfully

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)

VENKATASUBRAMAN  
IAN ARAVINDKUMAR  
Digitally signed by  
VENKATASUBRAMANIAN  
ARAVINDKUMAR  
Date: 2025.03.07 11:07:38 +05'30'



**ARAVINDKUMAR V**

**COMPANY SECRETARY & COMPLIANCE OFFICER**

**Annexure -1**

**Disclosure under Regulation 30(6) read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Particulars	Description
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Time Medical International Ventures (India) Pvt Ltd ("TMIV") is currently engaged in the business of manufacturing and supplying magnetic resonance imaging machines and preventive healthcare devices.  The turnover of TMIV for the financial year ended March 31, 2024 was 2,162.34 lakhs.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?  If yes, nature of interest and details thereof and whether the same is done at "arm's length"	TMIV, being a wholly owned subsidiary is a related party of the Company. The transaction falls within the ambit of related party transactions and is at arms' length.  Except to the extent of shares held by the Company in TMIV, the Company has no interest in TMIV.
3.	Industry to which the entity being acquired belongs	HealthCare
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment is a part of utilization of the proceeds as specified in Offer letter dated February 04, 2025 for working capital requirements of TMIV.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6.	Indicative time period for completion of the acquisition	Not applicable
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash
8.	Cost of acquisition or the price at which the shares are acquired	Investment of INR 220,90,59,177.50 (1,10,827 equity shares on rights basis).
9.	Percentage of shareholding/ control acquired and/or number of shares acquired	There will be no change in the percentage of shareholding of the Company in TMIV. It will continue to remain a wholly owned subsidiary of the Company.

10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>TMIV was incorporated on January 10, 2019 and became the wholly owned subsidiary of the Company in January 2024. TMIV is currently engaged in the business of manufacturing and supplying magnetic resonance imaging machines and preventive healthcare devices.</p> <p>The turnover of TMIV for last 3 years is given below: 2021-22: 0 2022-23: 32 Lakhs 2023-24: 2,162 Lakhs</p>
-----	--	--

